Vera Therapeutics Inc (NASDAQ: VERA)’s stock price has increased by 4.41 compared to its previous closing price of 42.05. However, the company has seen a -0.33% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-09 that BRISBANE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 171,750 shares of Class A common stock and restricted stock units (RSUs) for 86,625 shares of Class A common stock to seventeen new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Is It Worth Investing in Vera Therapeutics Inc (NASDAQ: VERA) Right Now?
Moreover, the 36-month beta value for VERA is 1.15. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VERA is 49.05M and currently, short sellers hold a 13.29% of that float. On December 20, 2024, VERA’s average trading volume was 748.92K shares.
VERA’s Market Performance
VERA’s stock has seen a -0.33% decrease for the week, with a -4.03% drop in the past month and a -1.47% fall in the past quarter. The volatility ratio for the week is 5.70%, and the volatility levels for the past 30 days are at 4.53% for Vera Therapeutics Inc The simple moving average for the past 20 days is -5.76% for VERA’s stock, with a 7.64% simple moving average for the past 200 days.
Analysts’ Opinion of VERA
Many brokerage firms have already submitted their reports for VERA stocks, with Wells Fargo repeating the rating for VERA by listing it as a “Overweight.” The predicted price for VERA in the upcoming period, according to Wells Fargo is $70 based on the research report published on November 21, 2024 of the current year 2024.
Oppenheimer gave a rating of “Outperform” to VERA, setting the target price at $26 in the report published on January 25th of the current year.
VERA Trading at -2.81% from the 50-Day Moving Average
After a stumble in the market that brought VERA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.93% of loss for the given period.
Volatility was left at 4.53%, however, over the last 30 days, the volatility rate increased by 5.70%, as shares sank -6.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.76% upper at present.
During the last 5 trading sessions, VERA rose by +0.17%, which changed the moving average for the period of 200-days by +1.91% in comparison to the 20-day moving average, which settled at $46.60. In addition, Vera Therapeutics Inc saw 185.47% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VERA starting from MARSHALL FORDYCE, who proposed sale 17,500 shares at the price of $43.91 back on Dec 18 ’24. After this action, MARSHALL FORDYCE now owns shares of Vera Therapeutics Inc, valued at $768,425 using the latest closing price.
Fordyce Marshall, the PRESIDENT AND CEO of Vera Therapeutics Inc, sale 17,500 shares at $46.94 during a trade that took place back on Dec 11 ’24, which means that Fordyce Marshall is holding 85,942 shares at $821,523 based on the most recent closing price.
Stock Fundamentals for VERA
The total capital return value is set at -0.42. Equity return is now at value -65.11, with -49.39 for asset returns.
Based on Vera Therapeutics Inc (VERA), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.39. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -21.33.
Currently, EBITDA for the company is -102.01 million with net debt to EBITDA at -0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.60.
Conclusion
To wrap up, the performance of Vera Therapeutics Inc (VERA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
